These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 26555315)
21. Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease. Horgan J; Miguel-Hidalgo JJ; Thrasher M; Bissette G J Alzheimers Dis; 2007 Sep; 12(2):115-27. PubMed ID: 17917156 [TBL] [Abstract][Full Text] [Related]
22. SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer's Disease. Trujillo-Estrada L; Vanderklish PW; Nguyen MMT; Kuang RR; Nguyen C; Huynh E; da Cunha C; Javonillo DI; Forner S; Martini AC; Sarraf ST; Simmon VF; Baglietto-Vargas D; LaFerla FM Neurotherapeutics; 2021 Oct; 18(4):2468-2483. PubMed ID: 34738197 [TBL] [Abstract][Full Text] [Related]
23. Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice. Dobarro M; Gerenu G; Ramírez MJ Int J Neuropsychopharmacol; 2013 Nov; 16(10):2245-57. PubMed ID: 23768694 [TBL] [Abstract][Full Text] [Related]
24. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease. Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172 [TBL] [Abstract][Full Text] [Related]
25. Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease. Mori T; Koyama N; Tan J; Segawa T; Maeda M; Town T J Biol Chem; 2017 Jul; 292(27):11310-11325. PubMed ID: 28512130 [TBL] [Abstract][Full Text] [Related]
26. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease. Peng Y; Sun J; Hon S; Nylander AN; Xia W; Feng Y; Wang X; Lemere CA J Neurosci; 2010 Jun; 30(24):8180-9. PubMed ID: 20554868 [TBL] [Abstract][Full Text] [Related]
28. Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer's disease mouse model. Li W; Yu J; Liu Y; Huang X; Abumaria N; Zhu Y; Huang X; Xiong W; Ren C; Liu XG; Chui D; Liu G J Neurosci; 2013 May; 33(19):8423-41. PubMed ID: 23658180 [TBL] [Abstract][Full Text] [Related]
29. Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model. Li W; Yu J; Liu Y; Huang X; Abumaria N; Zhu Y; Huang X; Xiong W; Ren C; Liu XG; Chui D; Liu G Mol Brain; 2014 Sep; 7():65. PubMed ID: 25213836 [TBL] [Abstract][Full Text] [Related]
30. A Novel Apolipoprotein E Antagonist Functionally Blocks Apolipoprotein E Interaction With N-terminal Amyloid Precursor Protein, Reduces β-Amyloid-Associated Pathology, and Improves Cognition. Sawmiller D; Habib A; Hou H; Mori T; Fan A; Tian J; Zeng J; Giunta B; Sanberg PR; Mattson MP; Tan J Biol Psychiatry; 2019 Aug; 86(3):208-220. PubMed ID: 31208706 [TBL] [Abstract][Full Text] [Related]
31. Gain of PITRM1 peptidase in cortical neurons affords protection of mitochondrial and synaptic function in an advanced age mouse model of Alzheimer's disease. Du F; Yu Q; Yan S; Zhang Z; Vangavaragu JR; Chen D; Yan SF; Yan SS Aging Cell; 2021 May; 20(5):e13368. PubMed ID: 33951271 [TBL] [Abstract][Full Text] [Related]
32. EphA4 loss improves social memory performance and alters dendritic spine morphology without changes in amyloid pathology in a mouse model of Alzheimer's disease. Poppe L; Rué L; Timmers M; Lenaerts A; Storm A; Callaerts-Vegh Z; Courtand G; de Boer A; Smolders S; Van Damme P; Van Den Bosch L; D'Hooge R; De Strooper B; Robberecht W; Lemmens R Alzheimers Res Ther; 2019 Dec; 11(1):102. PubMed ID: 31831046 [TBL] [Abstract][Full Text] [Related]
33. Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease. Caccamo A; Branca C; Talboom JS; Shaw DM; Turner D; Ma L; Messina A; Huang Z; Wu J; Oddo S J Neurosci; 2015 Oct; 35(41):14042-56. PubMed ID: 26468204 [TBL] [Abstract][Full Text] [Related]
34. Intermittent Hypoxic Conditioning Rescues Cognition and Mitochondrial Bioenergetic Profile in the Triple Transgenic Mouse Model of Alzheimer's Disease. Correia SC; Machado NJ; Alves MG; Oliveira PF; Moreira PI Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33466445 [TBL] [Abstract][Full Text] [Related]
35. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice. Kimura R; Devi L; Ohno M J Neurochem; 2010 Apr; 113(1):248-61. PubMed ID: 20089133 [TBL] [Abstract][Full Text] [Related]
37. Overexpression of Ubiquilin-1 Alleviates Alzheimer's Disease-Caused Cognitive and Motor Deficits and Reduces Amyloid-β Accumulation in Mice. Adegoke OO; Qiao F; Liu Y; Longley K; Feng S; Wang H J Alzheimers Dis; 2017; 59(2):575-590. PubMed ID: 28598849 [TBL] [Abstract][Full Text] [Related]
38. Effects of growth hormone-releasing hormone on sleep and brain interstitial fluid amyloid-β in an APP transgenic mouse model. Liao F; Zhang TJ; Mahan TE; Jiang H; Holtzman DM Brain Behav Immun; 2015 Jul; 47():163-71. PubMed ID: 25218899 [TBL] [Abstract][Full Text] [Related]
39. Depletion of Caveolin-1 in Type 2 Diabetes Model Induces Alzheimer's Disease Pathology Precursors. Bonds JA; Shetti A; Bheri A; Chen Z; Disouky A; Tai L; Mao M; Head BP; Bonini MG; Haus JM; Minshall RD; Lazarov O J Neurosci; 2019 Oct; 39(43):8576-8583. PubMed ID: 31527120 [TBL] [Abstract][Full Text] [Related]
40. SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease. Brunner D; Flunkert S; Neddens J; Duller S; Scopes DIC; Treherne JM; Hutter-Paier B Neurosci Lett; 2017 Nov; 660():96-102. PubMed ID: 28917978 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]